ArticlePharmaceutical research2026
Polar vs Non-polar Excipients in BSA Aggregation.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn recent years, there has been a rapid expansion in the development of new protein therapeutics in the pharmaceutical industry. Problematically, proteins are conformationally and colloidally marginally stable, and thus it is necessary to formulate them using buffering and stabilizing agents.
methodsIn this study, we use experimental and computation techniques to evaluate the aggregation pathway, as well as the stabilizing properties of a range of excipients on a model protein; bovine serum albumin (BSA).
resultsOur results show that polar excipients (L-arginine and trimethylamine N-oxide) decrease BSA stability, whereas non-polar excipients (L-alanine and L-valine) enhances it. To elucidate molecular mechanisms behind these trends, we constructed a multi-step unfolding and aggregation model. Upon thermal stress, the protein system is driven to form a disrupted dimer/trimer species across a steep activation energy barrier. This acts as the primary kinetic bottleneck, as once these intermediate states form sufficiently, large aggregates in tetramers and pentamers form across a significantly lower energy barrier. High temperature molecular dynamics simulations reveal that the unfolding mode of the monomer is characterized by the detachment of its C-terminus domain, creating an extended, aggregation prone structure. Crucially, in the native structure, this flexible region contains the only prominent solvent exposed hydrophobic patch on an otherwise hydrophilic protein surface. Therefore, hydrophobic excipients are predicted to interface with this hotspot, stabilizing the folded structure and suppressing downstream aggregation formation.
conclusionsOverall, this work demonstrates that understanding the specific protein aggregation mechanisms is key for the rational selection of stabilizers.
Indexed as
Identifiers
42844497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.